Angiogenesis targeting molecules
OwnerTheresa Fauconnier, Alfred Pollak +2inventors
InventorsTheresa Fauconnier, Alfred Pollak, John Thornback, Dennis Eshima
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds that are effective for targeting sites of angiogenesis for diagnostic and therapeutic purposes. The compounds are of the Formula (I) A-(B)n-C, wherein A is a chelator moiety capable of complexing a radionuclide metal or a moiety capable of binding to a halogen; B is a spacer group; C is an angiogenesis targeting molecule; and n is selected from the integers 0 and 1. The invention also relates to a method of imaging sites of angiogenesis and treating patients through the administration of the compounds of the present invention.
Claims35
A compound for the imaging and treatment of angiogenesis of the following formula (I):
- A-(B)n-C (I)
- wherein
- A is a chelator moiety capable of complexing a radionuclide metal or a moiety capable of binding to a halogen;
- B is a spacer group;
- C is an angiogenesis targeting molecule;
- and
- n is selected from the integers 0 and 1.
A compound comprising a metal chelating moiety and a moiety that binds to sites of angiogenesis.
A compound for the imaging and treatment of angiogenesis comprising VEGF labeled with an isotope of iodine, technetium, rhenium or an active ester of a metal chelate.
A compound for the imaging and treatment of angiogenesis comprising angiostatin, endostatin, angiopoietin-1, angiopoietin-2, PECAM-1, MMPs, ephrin-B2, osteopoietin, fibronectin, vitronectin, Cyr-61 or pronectin-V labeled with an isotope of iodine, technetium or rhenium.
Dependencies are inferred from the claim text.